Aeris Therapeutics has received expanded CE Mark approval in Europe for the AeriSeal System used to treat patients with emphysema.
The move follows the availability of new clinical data from a study in which patients received treatment in two regions in each lung during a single bronchoscopic procedure.
The AeriSeal system uses a proprietary polymer sealant delivered through a bronchoscope to the damaged areas of the patient’s lungs to reduce lung volume without surgery.
Aeris Therapeutics CEO David Dove said that the approval meant that clinicians are able to treat more damaged lung regions in a single treatment session, which results in better outcomes from a single minimally invasive procedure.
”We can now accelerate our global commercialisation and scale up of clinical education and training programmes and make this therapy available to more patients suffering from emphysema,” Dove said.
